SLC5A5 Antibody, FITC conjugated

Code CSB-PA835713LC01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) SLC5A5 Polyclonal antibody
Uniprot No.
Target Names
Alternative Names
Na(+)/I(-) cotransporter antibody; Na(+)/I(-) symporter antibody; Na+/I- cotransporter antibody; Na+/I-symporter antibody; NIS antibody; SC5A5_HUMAN antibody; Slc5a5 antibody; sodium iodide symporter antibody; Sodium-iodide symporter antibody; Sodium/iodide cotransporter antibody; Solute carrier family 5 (sodium iodide symporter) member 5 antibody; solute carrier family 5 (sodium/iodide cotransporter), member 5 antibody; Solute carrier family 5 member 5 antibody; TDH1 antibody
Raised in
Species Reactivity
Recombinant Human Sodium/iodide cotransporter protein (547-643AA)
Immunogen Species
Homo sapiens (Human)
Purification Method
>95%, Protein G purified
It differs from different batches. Please contact us to confirm it.
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Mediates iodide uptake in the thyroid gland.
Gene References into Functions
  1. The present work reveals much lower iodide affinity in the pocket of human SMCT1 analogous to the putative iodide-binding pocket of human NIS. PMID: 29131623
  2. The expression of NIS differs insignificantly in gastric tissue of obese and control individuals. PMID: 29631680
  3. NIS localization in the follicular lumen in nodular goiter patients PMID: 28190186
  4. Results show transgene induction under hypoxia in tumor cell spheroid models, or radioiodide uptake using sodium iodide symporter (NIS). PMID: 27458162
  5. Data suggest iodination of TG is involved in regulation of NIS expression in thyroid follicle via TSH/TSHR signaling; NIS expression and PKA activity are up-regulated by lowly iodinated TG; NIS expression is down-regulated and PKC activity up-regulated by highly iodinated TG. (TG, thyroglobulin; NIS, sodium/iodide symporter; PK, protein kinase; TSH, thyroid-stimulating hormone; TSHR, thyroid-stimulating hormone receptor) PMID: 28396984
  6. Data indicate that although fewer than 25% of cells expressed Na+/I- symporter (NIS), combining131I- with gemcitabine (GEMGEM/131I)- caused dramatic tumor regression in NIS-transduced breast cancer brain metastases (BCBMs). PMID: 27363025
  7. Experiments in whole cells demonstrated that these four residues participate in transport by NIS: mutations at these positions result in proteins that, although expressed at the plasma membrane, transport little or no I(-) These residues are conserved throughout the entire SLC5 family, to which NIS belongs, suggesting that they serve a similar function in the other transporters PMID: 27562170
  8. Study brings out molecular evidence showing that NIS is a direct target of wild-type p53 and its activation upon Doxorubicin drug exposure results in suppression of NIS expression and function in breast cancer cells. PMID: 28528452
  9. radiotracer accumulation in transfected cells correlated with the induction of hNIS and with the expression of miRNAs detected by real time PCR. PMID: 28493972
  10. Results indicate that Na+/I- symporter (NIS) can be used as an objective used as an objective criterion for determining the sensitivity of luminal B and basal breast cancer (BC)subtypes to neoadjuvant chemotherapy (NACT). PMID: 28361851
  11. Our findings indicated that hTERT promoter-driven expression of the NIS gene in HeLa cells led to 188Re uptake and therapeutic effects. Thus, NIS-based gene therapy and imaging using the hTERT promoter and 188Re may be possible. PMID: 27573304
  12. SLC5A5 was down-regulated in FTC and PTC. Its expression could be modulated by hsa-let-7f-5p. ATC showed a loss of SLC5A5/hsa-let7f-5p correlation PMID: 26960757
  13. Mutating the sites located on the C-terminal domain of the protein has no effect except for the creation of a diacidic motif that decreases the total NIS protein level without affecting its expression at the plasma membrane. PMID: 26831514
  14. Therefore, enhancing functional NIS by the increasing level of glycosylation may be suggested as a promising therapeutic strategy for cancer patients who show refractory response to conventional radioiodine treatment. PMID: 26599396
  15. Our results confirmed that NIS overexpression enhances the sensitivity of ER-negative breast cancer cells to radioiodide therapy. PMID: 25955347
  16. miR-146b-3p binds to the 3'-untranslated region of PAX8 and sodium/iodide symporter, leading to impaired protein translation and a subsequent reduction in iodide uptake. PMID: 26282166
  17. Study demonstrates an association of one variant and several haplotypes of the NIS gene with differentiated thyroid cancer. PMID: 26160439
  18. Data suggest that SLC5A5, SLC5A8 (sodium-coupled monocarboxylate transporter 1), and SLC26A4 (pendrin), the 3 known iodide transporters, are important in breast tissue metabolism in lactation and in breast neoplasms. [REVIEW] PMID: 26285906
  19. Real time PCR revealed that both cell lines express mRNA of lactoferrin receptors while flow cytometry and confocal microscopy showed the cells efficiently internalize bLf which upregulates NIS expression. PMID: 26213306
  20. Although the affinity of NIS for I- is low, it increases when Na+ is bound. NIS takes advantage of the extracellular Na+ concentration and the pronounced increase in its own affinity for I- and for the second Na+ elicited by binding of the first. PMID: 24888603
  21. concluded that NIS-mediated RAIU could be modulated by miR-146b; accordingly, miR-146b might serve as one of targets to enhance efficacy of radioactive therapy against poorly differential thyroid carcinoma PMID: 25960292
  22. In normal salivary gland, striated duct cells strongly expressed NIS. In Warthin's tumors, eosinophilic epithelial cells exhibited NIS expression, but expression was varied among cases. Tc-positive specimens were NIS+. Tc-negative specimens were NIS-. PMID: 25199743
  23. Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis. PMID: 24096868
  24. results indicate that the NIS mutation rate is very low in the Guangxi Zhuang Region, China, and it is necessary to study mutations of other genes that have major effects on thyroid dyshormonogenesis and have not as yet been studied in this population. PMID: 25465605
  25. Relatively weak melanoma-specific promoter directs high NIS activity in melanoma cell, however weaker cancer-specific promoters drive high NIS activity only in certain melanoma cell line. PMID: 25842835
  26. BRAF V600E inhibited NIS expression by the upregulation of its promoter methylation. Specific regions of CpG islands of NIS promoter in BRAF V600E harboring papillary thyroid carcinoma were highly methylated compared with surrounding normal tissue. PMID: 25378232
  27. Given the recent progress in the study of NIS regulation as molecular basis for new therapeutic approaches in extrathyroidal cancers. PMID: 24884806
  28. The expression of TSHR and NIS genes is differently controlled by multiple mechanisms, including epigenetic events elicited by major signaling pathways involved in thyroid tumorigenesis. PMID: 24353283
  29. NIS is a new ovarian cancer marker, opening a door for the use of radioiodide in the diagnosis and treatment of ovarian cancer patients. PMID: 24708099
  30. this study identified a new distal enhancer, NIS distal enhancer, that regulates gene expression through DNA methylation in thyroid cancer. PMID: 24432988
  31. The results suggest a a key structural role for the delta-amino group of R124 in the Na+/I- symporter's maturation and cell surface targeting. PMID: 23690546
  32. NIS expression is tightly modulated during the transition of intercalated to striated ducts and striated to excretory ducts in salivary ductal cells. NIS expression in salivary glands is decreased during inflammation and tumor formation PMID: 23441638
  33. Data indicate that Na+/I- symporter and type 3 iodothyronine deiodinase genes are expressed in term placenta and amniotic membrane. PMID: 23857380
  34. the NIS gene is a direct target of the p53 family. PMID: 24052075
  35. SLC5A5 is composed of 13 transmembrane helices and 643 amino acid residues in humans. (Review) PMID: 23988430
  36. Data indicate that interhelical interaction is required for Na(+)/I(-) symporter (NIS) folding and activity. PMID: 23650190
  37. Data from mutant recombinant proteins suggest that proto-oncogene PBF/PTTG1IP (pituitary tumor-transforming 1 interacting protein) is phosphoprotein and highlight importance of tyrosine residue Y174 in its interaction/co-localization with NIS. PMID: 23678037
  38. MEK inhibition leads to lysosome-mediated NIS protein degradation in human breast cancer cells PMID: 23404856
  39. The study indicates a positive link between hNIS and ER expression in breast cancer. PMID: 23342072
  40. NIS is highly expressed in early human trophoblast at the feto-maternal interface. PMID: 23174149
  41. Data indicate that MV-NIS, an oncolytic measles virus that encodes the human thyroidal sodium iodide symporter (NIS), deliver targeted radiotherapy to the tumor site and promote a localized bystander effect. above and beyond that achieved by MV alone. PMID: 23134812
  42. Data from various thyroid cancer cell lines suggest that PARP (poly(ADP-ribose) polymerase) inhibition increases NIS gene expression through a particular modulation of transcriptional regulatory mechanisms (i.e., specific histone modifications). PMID: 22982218
  43. Data indicate that expression of SLC5A5 in placenta is up-regulated during placentation; during the first trimester, SLC5A5 mRNA is low at 6 weeks and peaks at 12 weeks; expression of SLC5A5 protein increases with increased placental vascularization. PMID: 22954554
  44. Nevirapine may induce the up-regulation of NIS mRNA and TSHR mRNA in FRO anaplastic thyroid carcinoma cells. PMID: 22781452
  45. Molecular imaging of luciferase signal and sodium-iodide symporter imaging may be useful for in vivo optimization of bioenergetics in transplanted cells. PMID: 23255420
  46. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. PMID: 23117572
  47. our results established NIS as a carrier protein that interacts with a major cell signaling hub to facilitate tumor cell locomotion and invasion. PMID: 22962269
  48. The BRAF(V600E) mutation was associated with a statistically significant lower functional NIS protein expression in the classic variant of papillary thyroid carcinomas. PMID: 23163107
  49. CREM expression is increased in thyroid cancer tissue and may play a role in the downregulation of sodium iodide symporter expression in thyroid cancer acting at the transcriptional level PMID: 22510021
  50. analysis of subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues PMID: 22545753

Show More

Hide All

Involvement in disease
Thyroid dyshormonogenesis 1 (TDH1)
Subcellular Location
Membrane; Multi-pass membrane protein.
Protein Families
Sodium:solute symporter (SSF) (TC 2.A.21) family
Tissue Specificity
Expression is primarily in thyroid tissue, but also to a lower extent in mammary gland and ovary. Expression is reduced in tumors.
Database Links

HGNC: 11040

OMIM: 274400

KEGG: hsa:6528

STRING: 9606.ENSP00000222248

UniGene: Hs.584804

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To